Citations

Mayo Clinic

Showing 10 of 108572 citations.

Change in the Distance From the Axillary Nerve to the Glenohumeral Joint With Shoulder External Rotation or Abduction Position
Simone, Juan Pablo , Steinmann, Scott P. , Adams, Julie E. , Adams, Julie , Sanchez-Sotelo, Joaquin, Streubel, Philipp N. , Sánchez‐Sotelo, Joaquín , Adams, Julie E

HAND | October 13, 2016 | Volume: 12 | Issue: 4 | Pages: 395-400

10.1177/1558944716668849 | PMID 28644944 Get It

Background: This study investigated whether axillary nerve (AN) distance to the inferior border of the humeral head and inferior glenoid would change while placing the glenohumeral joint in different degrees of external rotation and abduction. Methods: A standard deltopectoral approach was performed on 10 fresh-frozen cadaveric specimens. The distance between AN and the inferior border of the humeral head and inferior glenoid while placing the shoulder in 0°, 45°, and 90° of external rotation or abduction was measured. Continuous variables for changes in AN position were compared with paired 2-tailed Student t test. Results: The mean distance between the AN and the humeral head with the shoulder in 0°, 45°, and 90° of external rotation and 0° of abduction was 13.77 mm (SD 4.31), 13.99 mm (SD 4.12), and 16.28 mm (SD 5.40), respectively. The mean distance between the AN and glenoid with the shoulder in 0°, 45°, and 90° of external rotation was 16.33 mm (SD 3.60), 15.60 mm (SD 4.19), and 16.43 (SD 5.35), respectively. The mean distance between the AN and the humeral head with the shoulder in 0°, 45°, and 90° of abduction and 0° of external rotation was 13.76 mm (SD 4.31), 10.68 mm (SD 4.19), and 3.81 mm (SD 3.08), respectively. The mean distance between the AN and glenoid with the shoulder in 0°, 45°, and 90° of abduction was 16.33 mm (SD 3.60), 17.66 mm (SD 5.80), and 12.44 mm (SD 5.57), respectively. Conclusions: The AN position relative to the inferior aspect of the glenohumeral joint does not significantly change despite position of external rotation. Increasing shoulder abduction over 45° decreases the distance from the glenohumeral joint to the AN and should be avoided.
Beta‐blockers improve survival outcomes in patients with multiple myeloma: a retrospective evaluation
Hwa, Yi L. , Shi, Qian , Kumar, Shaji , Lacy, Martha Q. , Kapoor, Prashant , Dingli, David , Go, Ronald S. , Hayman, Suzanne R. , Russell, Stephen J. , Lust, John A., Lin, Yi , Dispenzieri, Angela , Buadi, Francis K. , Go, Ronald S , Russell, Stephen, Gertz, Morie A. , Leung, Nelson , Gonsalves, Wilson I. , Rajkumar, S. Vincent , Dispenzieri, Angela , Russell, Stephen J , Shi, Qian , Dingli, David , Lin, Yi

American Journal of Hematology | October 13, 2016 | Volume: 92 | Issue: 1 | Pages: 50-55

10.1002/ajh.24582 | PMID 27733010 Get It

A preclinical study demonstrated anti‐proliferative and apoptotic effect of propranolol on multiple myeloma (MM) cell. Clinical studies suggested that beta‐blocker (BB) might impact the prognosis of breast, prostate, colorectal, ovarian, lung, and skin cancer. This retrospective study evaluated the effect of BB in MM disease‐specific survival (DSS) and overall survival (OS). Among 1,971 newly diagnosed MM patients seen at Mayo Clinic between 1995 and 2010, usage of BB and other cardiac (or antihypertensive) medications were abstracted. Cumulative incidence function and Kaplan–Meier method were used to estimate 5‐year cumulative incidence rate (CIR) of MM death and OS rate, respectively. Nine hundred and thirty (47.2%) patients had no intake of cardiac medications; 260 (13.2%) used BB alone; 343 (17.4%) used both BB/non‐BB cardiac medications; and 438 (22.2%) had non‐BB cardiac drugs. Superior MM DSS was observed in BB only users, compared to patients without any cardiac drugs ( , 0.53, 95% confidence interval [CI], 0.42–0.67, Padj.<0.0001) and non‐BB cardiac drugs users ( , 0.49, 95% CI, 0.38–0.63, Padj.<0.0001). Patients on both BB and other cardiac drugs showed superior DSS than non‐cardiac drugs users ( , 0.54, 95% CI, 0.44–0.67, Padj.<0.0001) and non‐BB cardiac drug users. ( , 0.50, 95% CI, 0.40–0.62, Padj.<0.0001). MM DSS did not differ between BB users with and without other cardiac drugs (Padj.=0.90). Multivariable analysis showed the same pattern for OS. In patients with MM, BB intake is associated with a reduced risk of disease‐specific death and overall mortality in comparison to non‐BB or no use of cardiac drugs. Am. J. Hematol. 92:50–55, 2017. © 2016 Wiley Periodicals, Inc.
DNMT3A mutations are associated with inferior overall and leukemia‐free survival in chronic myelomonocytic leukemia
Patnaik, Mrinal M. , Barraco, Daniela , Finke, Christy M. , Hanson, Curtis A. , Ketterling, Rhett P. , Gangat, Naseema , Tefferi, Ayalew , Lasho, Terra L. , Ketterling, Rhett P

American Journal of Hematology | October 13, 2016 | Volume: 92 | Issue: 1 | Pages: 56-61

10.1002/ajh.24581 | PMID 27733013 Get It

DNMT3A mutations are seen in ∼5% of patients with chronic myelomonocytic leukemia (CMML) and thus far, have had an indeterminate prognostic impact on survival. We carried out this study to assess the prognostic impact of DNMT3A mutations on a larger informative cohort of CMML patients (n = 261). DNMT3A mutations were seen in 6% (n = 16); 56% (n = 9) male, with a median age of 64 years. Eighty‐one % of DNMT3A mutations were missense, with the Arg882 mutational hot spot accounting for 63% of all changes. Five (31%) patients had an abnormal karyotype whereas concurrent gene mutations (SF3B1/SRSF2/U2AF1−56%, TET2−50%, and ASXL1−25%) were seen in all patients. Apart from a higher frequency of SF3B1 (P = 0.0001) and PTPN11 (P = 0.005) mutations and a lower frequency of SRSF2 (P = 0.004) mutations, there were no significant differences between DNMT3A mutated patients and their wildtype counterparts. In univariate analysis, survival was shorter in DNMT3A mutated (median 8 months) versus wildtype (median 27 months) patients (P = 0.0007; HR 2.9, 95% CI 1.5–5.7); with other variables of significance including lower hemoglobin (P = 0.002), higher leukocyte count (P = 0.0009), higher monocyte count (P = 0.0012), circulating blast % (P = 0.001), circulating immature myeloid cells (P = 0.01), bone marrow blast % (P = 0.045), abnormal karyotype (P = 0.02), and ASXL1 (P = 0.01) mutations. In a multivariable model that included the aforementioned variables, when both DNMT3A and ASXL1 mutations were added, only DNMT3A (P < 0.0001) and ASXL1 (P = 0.004) mutations remained significant. DNMT3A mutations were also predictive of a shortened leukemia‐free survival. These findings warrant inclusion of DNMT3A mutations in molecularly integrated CMML prognostic models. Am. J. Hematol. 92:56–61, 2017. © 2016 Wiley Periodicals, Inc.
Reply
Lynn, Amanda M., Leise, Michael D.

Liver Transplantation | October 13, 2016 | Volume: 22 | Issue: 12 | Pages: 1736-1737

10.1002/lt.24647 | PMID 27731936 Get It

Right Ventricular Dysfunction and Pulmonary Hypertension in Heart Failure with Preserved Ejection Fraction
Obokata, Masaru , Borlaug, Barry A. , Borlaug, Barry A , Obokata, Masaru

European Journal of Heart Failure | October 13, 2016 | Volume: 18 | Issue: 12 | Pages: 1488-1490

10.1002/ejhf.666 | PMID 27734560 Get It

Scapular flap for maxillectomy defect reconstruction and preliminary results using three‐dimensional modeling
Modest, Mara C., Moore, Eric J. , Abel, Kathryn M. Van , Janus, Jeffrey R. , Sims, John R. , Olsen, Kerry D., Price, Daniel L. , Van Abel, Kathryn M

The Laryngoscope | October 13, 2016 | Volume: 127 | Issue: 1 | Pages: No page available

10.1002/lary.26351 | PMID 27730644 Get It

Objectives/HypothesisDiscuss current techniques utilizing the scapular tip and subscapular system for free tissue reconstruction of maxillary defects and highlight the impact of medical modeling on these techniques with a case series.Study DesignCase review series at an academic hospital of patients undergoing maxillectomy + thoracodorsal scapula composite free flap (TSCF) reconstruction. Three‐dimensional (3D) models were used in the last five cases.Methods3D modeling, surgical, functional, and aesthetic outcomes were reviewed.ResultsNine patients underwent TSCF reconstruction for maxillectomy defects (median age = 43 years; range, 19–66 years). Five patients (55%) had a total maxillectomy (TM) ± orbital exenteration, whereas four patients (44%) underwent subtotal palatal maxillectomy. For TM, the contralateral scapula tip was positioned with its natural concavity recreating facial contour. The laterally based vascular pedicle was ideally positioned for facial vessel anastomosis. For subtotal‐palatal defect, an ipsilateral flap was harvested, but inset with the convex surface facing superiorly. Once 3D models were available from our anatomic modeling lab, they were used for intraoperative planning of the last five patients. Use of the model intraoperatively improved efficiency and allowed for better contouring/plating of the TSCF. At last follow‐up, all patients had good functional outcomes. Aesthetic outcomes were more successful in patients where 3D‐modeling was used (100% vs. 50%). There were no flap failures. Median follow‐up >1 month was 5.2 months (range, 1–32.7 months).ConclusionsReconstruction of maxillectomy defects is complex. Successful aesthetic and functional outcomes are critical to patient satisfaction. The TSCF is a versatile flap. Based on defect type, choosing laterality is crucial for proper vessel orientation and outcomes. The use of internally produced 3D models has helped refine intraoperative contouring and flap inset, leading to more successful outcomes.Level of Evidence4. Laryngoscope, 127:E8–E14, 2017
Early outcomes after cochlear implantation for adults and children with unilateral hearing loss
Sladen, Douglas P. , Carlson, Matthew L. , Dowling, Brittany P., Olund, Amy P., Teece, Kathryn, DeJong, Melissa D., Breneman, Alyce, Peterson, Ann M. , Beatty, Charles W., Neff, Brian A., Driscoll, Colin L. W., Teece, Katherine , Peterson, Ann, Driscoll, Colin L.

The Laryngoscope | October 13, 2016 | Volume: 127 | Issue: 7 | Pages: 1683-1688

10.1002/lary.26337 | PMID 27730647 Get It

Objectives/HypothesisThis study was designed to examine speech recognition and self‐perceived health‐related quality of life (HRQoL) received from cochlear implantation among a cohort of adults and children with a short duration of unilateral hearing loss greater than 6 months, but less than 2 years.Study DesignSingle‐subject repeated measures prospective study.MethodsThis study assessed changes in speech recognition and self‐perceived quality of life by prospectively analyzing data at the preoperative evaluation and at the 3‐month and 6‐month postactivation intervals. Measurement tools included Medical Outcomes Study Questionnaire Short Form 36, Nijmegen Cochlear Implant Questionnaire, Speech Spatial and Qualities of Hearing–Comparative, and speech recognition measures in quiet and in noise.ResultsResults indicated significant improvement in speech recognition, both in quiet and noise. Quality‐of‐life measures showed a significant increase in self‐perceived benefit with disease‐specific instruments, but remained constant with a generic HRQoL instrument.ConclusionsCochlear implantation was a successful intervention for improved hearing in quiet and noise, and a self‐perceived benefit for this group of adults and children with a short duration of unilateral hearing loss.Level of Evidence4 Laryngoscope, 127:1683–1688, 2017